HER2+ Breast Cancer

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

The combination of margetuximab and chemotherapy induced a 1.8-month median overall survival increase in patients with pretreated HER2-positive metastatic breast cancer compared with trastuzumab (Herceptin) and chemotherapy.

Tucatinib combined with trastuzumab and capecitabine improved overall survival and progression-free survival compared with trastuzumab/capecitabine alone in heavily pretreated patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Douglas K. Marks, MD, discusses investigational antibody–drug conjugates in HER2-positive breast cancer.

Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.

The FDA has granted a priority review designation to a biologics license application for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of patients with HER2-positive metastatic breast cancer.

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

Michael Untch, MD, PhD, discusses the primary findings from the phase III KATHERINE trial and the added impact of long-term safety data regarding the use of adjuvant T-DM1 in early-stage HER2-positive breast cancer.

Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Leisha A. Emens, MD, PhD, discusses the rationale behind the KATE2 study and the results that may signal clinical significance.

Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discusses the use of neratinib (Nerlynx) and capecitabine in patients with HER2-positive breast cancer that has metastasized to the brain.

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

The FDA has approved a labeling supplement for neratinib for the extended adjuvant treatment of patients with HER2-positive early-stage breast cancer.

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

Kelly E. Westbrook, MD, discusses the 3-year follow-up data on the KRISTINE trial in stage II or III HER2-positive breast cancer.

Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.

A fixed-dose subcutaneous injection of pertuzumab and trastuzumab with hyaluronidase in combination with intravenous chemotherapy demonstrated noninferior pharmacokinetics compared with the standard IV infusions of the regimen in patients with HER2-positive early breast cancer, meeting the primary endpoint of the phase III FeDeriCa trial (NCT03493854).

Neelima Denduluri, MD, medical oncologist, Virginia Cancer Specialists, discusses the role of neoadjuvant therapy in HER2-positive breast cancer and triple-negative breast cancer.

The FDA has accepted a supplemental new drug application for neratinib for use in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed at least 2 prior lines of HER2-directed treatments.

Douglas K. Marks, MD, discusses data from a small subset of patients with HER2-positive breast cancer enrolled in the PHENIX trial, which was presented at the 2019 ASCO Annual Meeting.

Douglas K. Marks, MD, discusses key developments in the HER2-positive breast cancer space and shed light on novel approaches under investigation.

Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.

Combining pyrotinib with capecitabine reduced the risk of disease progression or death by 64% compared with lapatinib (Tykerb) plus capecitabine in Chinese patients with relapsed or metastatic HER2-positive breast cancer.

Hope S. Rugo, MD, discusses the findings from the phase III SOPHIA trial and the potential impact of margetuximab on HER2-positive metastatic breast cancer.

Keerthi Gogineni, MD, MSHP, an assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses de-escalation strategies in HER2-positive breast cancer.

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses [fam-] trastuzumab deruxtecan in HER2-positive breast cancer.

Tessa Cigler, MD, MPH, discusses the agents that are improving survival for women with early-stage and metastatic HER2-positive breast cancers.

Manali Bhave, MD, highlights the novel agents under investigation in the treatment of patients with metastatic HER2-positive breast cancer.

Michel Velez, MD, provides perspective on the clinical experience with neratinib in patients with early-stage HER2-positive breast cancer as well as promising data that may lead to an indication in the metastatic setting.